AI Article Synopsis
- Ovarian cancer is a leading cause of cancer deaths in women, emphasizing the need for new drug treatments to improve patient outcomes.
- Patient-derived organoid (PDO) models offer an advanced approach for drug screening in ovarian cancer, as they better mimic the tumor environment and are more cost-effective compared to other methods.
- A method utilizing a luminescence-based ATP assay is described for testing drug effectiveness on ovarian cancer PDOs, allowing for quicker evaluations within 7-10 days.
Article Abstract
Ovarian cancer is a fatal gynecologic cancer and the fifth leading cause of cancer death among women in the United States. Developing new drug treatments is crucial to advancing healthcare and improving patient outcomes. Organoids are in-vitro three-dimensional multicellular miniature organs. Patient-derived organoid (PDO) models of ovarian cancer may be optimal for drug screening because they more accurately recapitulate tissues of interest than two-dimensional cell culture models and are inexpensive compared to patient-derived xenografts. In addition, ovarian cancer PDOs mimic the variable tumor microenvironment and genetic background typically observed in ovarian cancer. Here, a method is described that can be used to test conventional and novel drugs on PDOs derived from ovarian cancer tissue and ascites. A luminescence-based adenosine triphosphate (ATP) assay is used to measure viability, growth rate, and drug sensitivity. Drug screens in PDOs can be completed in 7-10 days, depending on the rate of organoid formation and drug treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10881228 | PMC |
| http://dx.doi.org/10.3791/65068 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!